Title:
ERCC1発現に基づく化学療法による処方の決定方法
Document Type and Number:
Japanese Patent JP2004518429
Kind Code:
A
Abstract:
The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair ERCC1 and methods comprising their use for detecting levels of ERCC1 mRNA.
More Like This:
| WO/2019/043177 | SPIROTHIETANE NUCLEOSIDES |
| JP2019536767 | Composition containing a combination of epicatechin and anti-cancer compound |
| WO/2013/143000 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
Inventors:
Dannenberg, Kathleen Dee.
Application Number:
JP2002561063A
Publication Date:
June 24, 2004
Filing Date:
November 29, 2001
Export Citation:
Assignee:
Response Genetics, Incorporated
International Classes:
A61K31/7068; A61K33/24; A61P35/00; C12N15/09; C12Q1/68; G01N33/50; G01N33/574; C12Q; (IPC1-7): C12N15/09; A61K31/7068; A61K33/24; A61P35/00; C12Q1/68; G01N33/50
Domestic Patent References:
| JPH0870892A | 1996-03-19 |
Foreign References:
| US5705336A | 1998-01-06 |
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Tetsuji Koga
Masaya Nishiyama
Takashi Ishida
Tetsuji Koga
Masaya Nishiyama